Effectiveness and Safety of the Insulin Degludec U100 vs. Glargine U300 in People with Type 1 diabetes-The IneoxPlus Real-World Study

被引：1
|
作者：
De Adana, Maria S. Ruiz, Sr.
Dominguez-Lopez, Marta E.
Mora, Maria Del Rosario Vallejo
Colomo, Natalia
Linares, Francisca
Morillas, Virginia
Herrera, Maria Jose Vallejo
Gallardo, Silvia Patricia Alonso
Fuentes, Maria Teresa Padilla
Vela, Luis I. Navas
Maldonado-Araque, Cristina
Olveira, Gabriel
Martinez, Gemma Rojo
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-1803-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1803-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [1] More Consistent Antilipolitic and Antiketogenetic Action of Insulin Glargine U300 vs. U100 in Type 1 Diabetes
    Lucidi, Paola
    Candeloro, Paola
    Andreoli, Anna Marinelli
    Cioli, Patrizia
    Bolli, Geremia B.
    Fanelli, Carmine G.
    Porcellati, Francesca
    DIABETES, 2017, 66 : A270 - A270
  • [2] Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naive Patients with Type 2 Diabetes Mellitus: DosInGlar Study
    Duque, Natalia
    Artime, Esther
    Romera, Irene
    Lebrec, Jeremie
    Diaz, Silvia
    Rubio, Miriam
    Sicras-Mainar, Antoni
    Carretero-Anibarro, Enrique
    Mundet, Xavier
    Gorgojo-Martinez, Juan J.
    Reviriego, Jesus
    ADVANCES IN THERAPY, 2021, 38 (07) : 3857 - 3871
  • [3] More consistent antilipolitic and antiketogenetic action of insulin Glargine U300 vs U100 in type 1 diabetes
    Lucidi, P.
    Candeloro, P.
    Andreoli, A. Marinelli
    Cioli, P.
    Bolli, G. B.
    Fanelli, C. G.
    Porcellati, F.
    DIABETOLOGIA, 2017, 60 : S307 - S307
  • [4] Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study
    Natalia Duque
    Esther Artime
    Irene Romera
    Jeremie Lebrec
    Silvia Díaz
    Miriam Rubio
    Antoni Sicras-Mainar
    Enrique Carretero-Anibarro
    Xavier Mundet
    Juan J. Gorgojo-Martínez
    Jesús Reviriego
    Advances in Therapy, 2021, 38 : 3857 - 3871
  • [5] More Physiological Circulating Insulin and Modulation of Hepatic Glucose Production with Insulin Glargine U300 vs. U100 in Type 1 Diabetes
    Porcellati, Francesca
    Lucidi, Paola
    Andreoli, Anna Marinelli
    Cioli, Patrizia
    Candeloro, Paola
    Bolli, Geremia B.
    Fanelli, Carmine G.
    DIABETES, 2017, 66 : A269 - A269
  • [6] Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison
    Yi Martin
    Tatsuya Zhou
    Yu-Shi Takagi
    International Journal of Clinical Pharmacy, 2022, 44 : 587 - 598
  • [7] Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison
    Martin
    Zhou, Yi
    Takagi, Tatsuya
    Tian, Yu-Shi
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (03) : 587 - 598
  • [8] A Comparison of Insulin Glargine U300 and Insulin Degludec around Spontaneous Exercise Sessions in People with Type 1 Diabetes-The ULTRAFLEXI-1 Study
    Moser, Othmar
    Mueller, Alexander
    Aberer, Felix
    Aziz, Faisal
    Kojzar, Harald
    Sourij, Caren
    Obermayer, Anna M.
    Abbas, Farah M.
    Birnbaumer, Philipp
    Eckstein, Max L.
    Honger, Lukas
    Lenz, Jacqueline
    Mursic, Ines
    Sternad, Christoph
    Zanker, Matthias
    Ziko, Haris
    Pferschy, Peter N.
    Tripolt, Norbert J.
    Sourij, Harald
    DIABETES, 2022, 71
  • [9] More physiological circulating insulin and modulation of hepatic glucose production with insulin Glargine U300 vs U100 in type 1 diabetes
    Porcellati, F.
    Lucidi, P.
    Andreoli, A. Marinelli
    Cioli, P.
    Candeloro, P.
    Bolli, G. B.
    Fanelli, C. G.
    DIABETOLOGIA, 2017, 60 : S307 - S308
  • [10] Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
    Evans, Marc
    Mehta, Roopa
    Gundgaard, Jens
    Chubb, Barrie
    DIABETES THERAPY, 2018, 9 (05) : 1919 - 1930
12345